MedTrace Logo

Effects of ECT on Monoamine Oxidase A in Depression Investigated With PET

NCT02379767 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 27

Last updated 2019-08-28

No results posted yet for this study

Summary

This study aims at evaluating the effect of electroconvulsive therapy in treatment-resistant depressed patients on the major serotonin degrading enzyme in the human brain using neuroimaging methods, the monoamine oxidase A. Electroconvulsive therapy is an effective treatment option in severe cases of depression. However, the mechanisms underlying its effect remain uncertain, though variations within the serotonergic neurotransmitter system seem to be crucially involved.

Conditions

Interventions

DEVICE

Electroconvulsive therapy

OTHER

Positron emission tomography of the brain using [11C]harmine

OTHER

Structural magnetic resonance imaging

Sponsors & Collaborators

  • Medical University of Vienna

    lead OTHER

Eligibility

Min Age
16 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-03-31
Primary Completion
2018-05-25
Completion
2018-05-25

Countries

  • Austria

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02379767 on ClinicalTrials.gov